Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Insights, Forecast to 2028

Biologics CDMO Market 

The global Biologics CDMO Market size is projected to reach USD 23690 Million by 2028, from USD 11310 Million in 2021, at a CAGR of 10.9% during 2022-2028.

In this emerging in the form of cooperation, biological medicine industry further extended to the biological agents in the form of outsourcing cooperation contract development and manufacturing organization (CDMO) mode, the CDMO from preclinical studies and clinical trials to commercial production stage and the enterprise research and development, procurement, production, such as depth of the whole supply chain system docking, provide enterprises with innovative technology research and development and large-scale production services, in the higher value-added technology output instead of the pure output capacity.

Fully considering the economic change by this health crisis, Biologics Contract Development Services accounting for % of the Biologics Contract Development and Manufacturing Organization(CDMO) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Big Pharma segment is altered to an % CAGR throughout this forecast period.

China Biologics Contract Development and Manufacturing Organization(CDMO) market size is valued at US$ million in 2021, while the North America and Europe Biologics Contract Development and Manufacturing Organization(CDMO) are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Biologics Contract Development and Manufacturing Organization(CDMO) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologics Contract Development and Manufacturing Organization(CDMO) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologics Contract Development and Manufacturing Organization(CDMO) market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologics Contract Development and Manufacturing Organization(CDMO) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologics Contract Development and Manufacturing Organization(CDMO) market.

Global Biologics Contract Development and Manufacturing Organization(CDMO) Scope and Market Size

Biologics Contract Development and Manufacturing Organization(CDMO) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Biologics Contract Development and Manufacturing Organization(CDMO) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

By Type

• Biologics Contract Development Services
• Biologics Contract Manufacturing Services

By Application

• Big Pharma
• Small Pharma
• Generic Pharma
• Other

By Company

• Lonza
• Hansen
• Boehringer Ingelheim BioXcellence
• Thermo Fisher Scientific
• Samsung BioLogics
• AGC Biologics
• Catalent
• Wuxi Biologics

By Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA